Trial Profile
Does adjuvant zoledronate reduce recurrence in patients with high-risk localised breast cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jun 2023
Price :
$35
*
At a glance
- Drugs Zoledronic acid (Primary) ; Antineoplastics
- Indications Advanced breast cancer; Early breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms AZURE
- 25 May 2021 Status changed from active, no longer recruiting to completed.
- 31 May 2020 Results assessing MAF biomarker for response prediction by using data from two studies including this study presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 07 Feb 2018 Results of a study assessing predictive role of serum bone biomarkers in identifying patients with a high risk of developing bone metastasis published in the Journal of the National Cancer Institute